These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30391234)

  • 21. [Weight change, cardiometabolic risk and the impact of antidiabetic medications in type 2 diabetic patients].
    Danchin N; Eschwège E; Bekka S; Krempf M
    Ann Cardiol Angeiol (Paris); 2010 Aug; 59(4):214-20. PubMed ID: 20691966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity.
    Villalobos-Labra R; Subiabre M; Toledo F; Pardo F; Sobrevia L
    Mol Aspects Med; 2019 Apr; 66():49-61. PubMed ID: 30472165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
    Wang J; Ciaraldi TP; Samad F
    J Obes; 2015; 2015():291209. PubMed ID: 25861467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired signalling pathways mediated by extracellular vesicles in diabesity.
    Sáez T; Toledo F; Sobrevia L
    Mol Aspects Med; 2019 Apr; 66():13-20. PubMed ID: 30610887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
    Scheen AJ; Van Gaal LF
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus.
    Kaur P; Mittal A; Nayak SK; Vyas M; Mishra V; Khatik GL
    Curr Drug Targets; 2018; 19(15):1738-1766. PubMed ID: 30051787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabesity.
    Kalra S
    J Pak Med Assoc; 2013 Apr; 63(4):532-4. PubMed ID: 23905459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?
    Campbell IW
    Int J Clin Pract; 2010 May; 64(6):791-801. PubMed ID: 20518953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 2 diabetes mellitus and Invokana: an FDA approved drug.
    Akhtar N
    Curr Diabetes Rev; 2013 Nov; 9(6):478-90. PubMed ID: 24160357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioma progression in diabesity.
    Alarcón S; Niechi I; Toledo F; Sobrevia L; Quezada C
    Mol Aspects Med; 2019 Apr; 66():62-70. PubMed ID: 30822432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes under control: Understanding oral antidiabetic agents.
    Longo R
    Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
    [No Abstract]   [Full Text] [Related]  

  • 34. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabesity and mood disorders: Multiple links through the microbiota-gut-brain axis.
    Farzi A; Hassan AM; Zenz G; Holzer P
    Mol Aspects Med; 2019 Apr; 66():80-93. PubMed ID: 30513310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics.
    Bugáňová M; Pelantová H; Holubová M; Šedivá B; Maletínská L; Železná B; Kuneš J; Kačer P; Kuzma M; Haluzík M
    J Endocrinol; 2017 Apr; 233(1):93-104. PubMed ID: 28138003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered foetoplacental vascular endothelial signalling to insulin in diabesity.
    Pardo F; Subiabre M; Fuentes G; Toledo F; Silva L; Villalobos-Labra R; Sobrevia L
    Mol Aspects Med; 2019 Apr; 66():40-48. PubMed ID: 30849412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
    Karak M; Bal NC; Bal C; Sharon A
    Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.